Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an asymptomatic population: A randomized clinical trial

Chouhdari et al., Social Determinants of Health, doi:10.22037/sdh.v10i1.43032, IRCT20200421047153N1
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 80% Improvement Relative Risk Case 43% HCQ  Chouhdari et al.  Prophylaxis  DB RCT Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Double-blind RCT 1,000 patients in Iran (August - October 2020) Fewer cases with HCQ (p=0.005) c19hcq.org Chouhdari et al., Social Determinants .., Jan 2024 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
RCT of 1,000 people showing lower risk of COVID-19 infection with HCQ prophylaxis. There was no significant difference in side effects or adherence, no severe side effects, and blinding was well maintained.
There are now 13 PrEP RCTs, showing significant efficacy for COVID-19 cases with p = 0.000231.
risk of hospitalization, 80.1% lower, RR 0.20, p = 0.25, treatment 0 of 439 (0.0%), control 2 of 432 (0.5%), NNT 216, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of case, 42.8% lower, RR 0.57, p = 0.005, treatment 36 of 439 (8.2%), control 61 of 432 (14.1%), NNT 17, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chouhdari et al., 21 Jan 2024, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 14 authors, study period 20 August, 2020 - 20 October, 2020, dosage 800mg day 1, 200mg day 8, 200mg day 15, 200mg day 22, 200mg day 29, 200mg day 36, 200mg day 43, trial IRCT20200421047153N1.
This PaperHCQAll
The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an asymptomatic population: A randomized clinical trial
Termeh Tarjoman, Mahnaz Valizadeh, Parisa Shojaei, Behnam Farhoo, Mehrangi Zange, Masood Naj, Seyed Hamid Jamaldi, Masoumeh Mesgar, Za Hanifezadeh, Fae Abdollahi, Hamidreza Massumi Naini, Mohsen Alijani, Hasti Ziaee, Dr Arezoo Chouhdari
doi:10.22037/sdh.v10i1.43032
Background: Laboratory and observational data suggest that hydroxychloroquine (HCQ) has biological activity against SARS-CoV-2, potentially permitting its use for disease prevention. This study aimed to evaluate the hydroxychloroquine effect as prophylaxis for SARS-CoV-2 infection. Methods: This double-blind randomized controlled trial was performed on 1000 people between 18-65 who were not suspected of having COVID-19 symptoms at the time of enrollment and had no positive COVID-19 virus test. Hydroxychloroquine or placebo tablets (800 mg/d for the first day followed by 200 mg/d for 6 weeks) were prescribed randomly for participants in 2 groups and followed for 10 weeks. Results: Among 871 participants who were followed within 10 weeks 97(11.1%) became SARS-CoV-2 positive. there were statistically significant differences between infected or noninfected in the hydroxychloroquine (36 of 97 [37.1%]) and placebo (61 of 97 [62.9 %]) groups with a risk ratio of 2.1 (95% confidence interval (CI) 1.01 -3.21; p = 0.005). The incidence of severe forms of COVID-19 (i.e., hospitalized in the coronavirus ward or the ICU) was 2 of 97 (0.02 %) in participants who received a placebo compared to hydroxychloroquine. The proportion of non-infected people who received hydroxychloroquine prophylaxis was nearly twice higher than that of placebo users (1.87, 95% CI: 1.19 -2.84, p = 0.05). There were no significant differences between the two groups regarding side effects (1.1% vs. 0.9%), and no severe adverse reactions were observed. Conclusion: Pre-exposure therapy with hydroxychloroquine appears to prevent moderate and severe illness caused by COVID-19 in asymptomatic persons.
Author's contribution data analysis and interpretation: Arezoo Chouhdari; statistical analysis: Arezoo Chouhdari; supervision or mentorship: Termeh Tarjoman, Arezoo Chouhdari; write the first draft of the manuscript: Termeh Tarjoman, Arezoo Chouhdari; All authors contributed to the intellectual content, and manuscript editing and read and approved the final manuscript. Ethical considerations Questionnaires were filled with the participants' satisfaction and written consent was obtained from the participants in this study. Conflicts of interest All authors declare no conflict of interest.
References
Bansal, Goyal, Cusick, Lahan, Dhaliwal et al., Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019, Annals of medicine
Bhatt, Patel, Shah, Parikh, Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers, medRxiv
Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, Journal of medicinal chemistry
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, The New England journal of medicine
Cao, Deng, -X, Dai, Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence, Travel medicine and infectious disease
Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants, International journal of antimicrobial agents
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medrxiv
Cohen, Hydroxychloroquine for the Prevention of Covid-19 -Searching for Evidence, The New England journal of medicine
Cortegiani, Ippolito, Ingoglia, Iozzo, Giarratano et al., Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19, Journal of critical care
De Francia, Chiara, COVID-19 Prevention and Treatment, MDPI
Dhibar, Arora, Kakkar, Singla, Mohindra et al., Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study, International journal of antimicrobial agents
Honein, Rose, Brooks, Meaney-Delman, Cohn, Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020, MMWR Morbidity and mortality weekly report
Horby, Mafham, Linsell, Bell, Staplin et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Huang, Li, Leung, Liu, Liu et al., A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19), Pharmacological research
Jung, Kim, Kim, Choi, Chung et al., Effect of hydroxychloroquine preexposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study, Clinical Microbiology and Infection
Kashour, Kashour, Gerberi, Tleyjeh, Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Clinical and translational science
Khuroo, Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal, International journal of antimicrobial agents
Kloc, Ghobrial, Kubiak, The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection, International archives of allergy and immunology
Lammers, Brohet, Theunissen, Koster, Rood et al., Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Marmor, Kellner, Lai, Melles, Mieler, Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision), Ophthalmology
Monti, Vertogen, Masini, Donati, Lilli et al., Hydroxychloroquine as prophylaxis for COVID-19: a review, Frontiers in pharmacology
Naggie, Milstone, Castro, Collins, Lakshmi et al., Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebocontrolled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ), International Journal of Infectious Diseases
Najjar-Debbiny, Gronich, Weber, Khoury, Amar et al., Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients, Clinical Infectious Diseases
Panahi, Gorabi, Talaei, Beiraghdar, Akbarzadeh et al., An overview on the treatments and prevention against COVID-19, Virology Journal
Peeri, Shrestha, Rahman, Zaki, Tan et al., The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?, International journal of epidemiology
Polo, García-Albéniz, Terán, Morales, Rial-Crestelo et al., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers, Clinical Microbiology and Infection
Pradhan, Olsson, Sex differences in severity and mortality from COVID-19: are males more vulnerable?, Biology of sex differences
Rentsch, Devito, Mackenna, Morton, Bhaskaran et al., Effect of preexposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform, The Lancet Rheumatology
Ruggieri, Anticoli, 'ambrosio, Giordani, Viora, The influence of sex and gender on immunity, infection and vaccination, Annali dell'Istituto superiore di sanita
Sen, Werner, Shekhar, Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy. Drugs & therapy perspectives : for rational drug selection and use
Shabani, Totonchi, Rezaeimirghaed, Gachkar, Hajiesmaeili et al., Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19, Pulm Pharmacol Ther
Shabani, Totonchi, Rezaeimirghaed, Gachkar, Hajiesmaeili et al., Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19, Pulmonary Pharmacology & Therapeutics
Smit, Marinosci, Agoritsas, Calmy, Prophylaxis for COVID-19: a systematic review, Clinical microbiology and infection
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell research
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the, Infectious Diseases Society of America
{ 'type': 'article-journal', 'language': 'eng', 'author': [ {'family': 'Tarjoman', 'given': 'Termeh'}, {'family': 'Valizadeh', 'given': 'Mahnaz'}, {'family': 'Shojaei', 'given': 'Parisa'}, {'family': 'Farhoodi', 'given': 'Behnam'}, {'family': 'Zangeneh', 'given': 'Mehrangiz'}, {'family': 'Najafi', 'given': 'Masood'}, {'family': 'Jamaldini', 'given': 'Seyed Hamid'}, {'family': 'Mesgarian', 'given': 'Masoume'}, {'family': 'Hanifezadeh', 'given': 'Zahra'}, {'family': 'َAbdollahi', 'given': 'Faezeh'}, {'family': 'Massumi Naini', 'given': 'Hamidreza'}, {'family': 'Alijani', 'given': 'Mohsen'}, {'family': 'Ziaee', 'given': 'Hasti'}, {'family': 'Chouhdari', 'given': 'Arezoo'}], 'issued': {'date-parts': [[2024, 1, 21]]}, 'abstract': 'Background: Laboratory and observational data suggest that hydroxychloroquine (HCQ) has ' 'biological activity against SARS-CoV-2, potentially permitting its use for disease ' 'prevention. This study aimed to evaluate the hydroxychloroquine effect as prophylaxis for ' 'SARS-CoV-2 infection. Methods: In this double-blind randomized controlled trial, \xa01000 \xa0' 'healthy people without any signs and symptoms of COVID-19 were randomly assigned in a 1:1 ' 'ratio to receive either 800 mg hydroxychloroquine or placebo (four 200 mg tablets in two ' 'divided doses on day 1 of the first week, followed by 200 mg (in a single dose) weekly for ' 'the next 6 weeks). Results: Among 871 participants who remained and followed within 10 weeks ' '97(11.1%) became SARS-CoV-2 positive. there were statistically significant differences ' 'between infected or non-infected in the hydroxychloroquine (36 of 97 [37.1%]) and placebo (61 ' 'of 97 [62.9 %]) groups with a risk ratio of 2.1 (95% confidence interval (CI) 1.01 - 3.21; p ' '= 0.005). The incidence of severe forms of COVID-19 ( hospitalized in the coronavirus ward or ' 'the ICU) was 2 of 97 (0.02 %) in participants who received a placebo compared to ' 'hydroxychloroquine. The proportion of non-infected people who received hydroxychloroquine ' 'prophylaxis was nearly twice higher than that of placebo users (1.87, 95% CI: 1.19 - 2.84, p ' '= 0.05). There were no significant differences between the two groups regarding side effects ' '(1.1% vs. 0.9%), and no severe adverse reactions were observed. Conclusion: Pre-exposure ' 'therapy with hydroxychloroquine appears to prevent moderate and severe illness caused by ' 'COVID-19 in asymptomatic persons.', 'container-title': 'Social Determinants of Health', 'DOI': '10.22037/sdh.v10i1.43032', 'ISSN': '2423-7337', 'issue': 'Vol. 10 (2024): Continuous Issue', 'medium': 'JD', 'publisher': 'Social Determinants of Health Research Center, Shahid Beheshti University of Medical ' 'Sciences.', 'publisher-place': 'IR', 'title': 'The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an ' 'asymptomatic population: A randomized clinical trial', 'URL': 'https://doi.org/10.22037/sdh.v10i1.43032', 'volume': '10'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit